MIMI I-NAN HU to Prognosis
This is a "connection" page, showing publications MIMI I-NAN HU has written about Prognosis.
Connection Strength
0.101
-
Update on medullary thyroid cancer. Endocrinol Metab Clin North Am. 2014 Jun; 43(2):423-42.
Score: 0.035
-
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 08; 9(8):491-501.
Score: 0.014
-
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in?sporadic medullary thyroid carcinoma. Surgery. 2020 01; 167(1):80-86.
Score: 0.013
-
Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head Neck. 2018 Jan; 40(1):79-85.
Score: 0.011
-
Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017 09 01; 102(9):3591-3599.
Score: 0.011
-
Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4461-4467.
Score: 0.010
-
Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience. Cancer. 2011 Oct 01; 117(19):4381-9.
Score: 0.007